NeuroDerm

NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.

NeuroDerm is the first to develop liquid levodopa (LD), the gold standard treatment for Parkinson’s disease, thus, enabling for the first time continuous sub-cutaneous (SC) administration of this drug. By overcoming levodopa’s biggest deficiency – a short half-life – NeuroDerm’s products should transform patients’ lives, offering them clinical benefits that can only be obtained today by undergoing highly invasive surgery.

Latest Updates

Phase 3 clinical trial evaluating ND0612 (Continuous Subcutaneous Levodopa/Carbidopa) initiated in the United States for patients with Parkinson’s disease experiencing motor fluctuations

Phase 3 clinical trial evaluating ND0612 (Continuous Subcutaneous Levodopa/Carbidopa) initiated in the United States for patients with Parkinson’s disease experiencing motor fluctuations

Read press release

NeuroDerm Presents Two Posters at the 5th World Parkinson’s Congress in Kyoto, Japan

NeuroDerm Presents Two Posters at the 5th World Parkinson’s Congress in Kyoto, Japan

NeuroDerm had the pleasure of presenting 2 scientific posters on ND0612 at the 5th World Parkinson’s Congress held in Kyoto, Japan from June 4th to 7th.  The late-breaking posters focused on the study design of the new BouNDless pivotal efficacy trial and the new results of the pharmacokinetic ND0612-114 study.  Both posters can be found HERE.

NeuroDerm Initiates New Global Phase III Efficacy and Safety Trial

NeuroDerm Initiates New Global Phase III Efficacy and Safety Trial

In continuation of the clinical research efforts to demonstrate safety and efficacy of ND0612, NeuroDerm has initiated its new phase III BouNDless study.  Details on this double-blind, double-dummy pivotal efficacy trial can be found on clinicaltrials.gov

AAN 2018, LA – Oral presentation Efficacy and safety of subcutaneous L-dopa/carbidopa (ND0612H) infusion in fluctuating PD patients.

AAN 2018, LA – Oral presentation Efficacy and safety of subcutaneous L-dopa/carbidopa (ND0612H) infusion in fluctuating PD patients.

NeuroDerm was acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in cash. MTPC is a publicly traded company on the Tokyo Stock Exchange

NeuroDerm was acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in cash. MTPC is a publicly traded company on the Tokyo Stock Exchange

Our Solutions

NeuroDerm is developing products that address deficiencies in current treatments for the growing population of moderate to severe Parkinson’s disease patients.
NeuroDerm is the first company to develop a liquid formulation of levodopa/carbidopa (LD/CD). Based on this novel formulation, the company has developed LD/CD products administered through a patch-pump or small belt pump, designed to deliver a continuous, controlled dose of LD/CD. The LD/CD line of products includes: ND0612 as a low dose and a high dose for moderate to severe Parkinson’s disease patients.